Dashboard
Manage Tickers

GYRE GYRE THERAPEUTICS, INC.

Nasdaq www.gyretx.com


$ 7.94 $ -0.07 (-0.81 %)    

Wednesday, 12-Nov-2025 12:21:39 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 620.93 $ -3.85 (-0.62 %)
DIA $ 483.68 $ 3.12 (0.65 %)
SPY $ 683.67 $ -1.12 (-0.16 %)
TLT $ 90.29 $ 0.34 (0.38 %)
GLD $ 386.95 $ 6.80 (1.79 %)
$ 8.01
$ 8.00
$ 8.00 x 175
$ 8.09 x 10
$ 7.81 - $ 8.00
$ 6.11 - $ 19.00
49,416
na
771.63M
$ 6.84
$ 116.02
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-07-2025 09-30-2025 10-Q
2 08-11-2025 06-30-2025 10-Q
3 05-09-2025 03-31-2025 10-Q
4 03-17-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 03-27-2024 12-31-2023 10-K
9 10-26-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-30-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 03-31-2022 12-31-2021 10-K
17 11-12-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 03-04-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 02-20-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 05-02-2019 03-31-2019 10-Q
28 03-08-2019 12-31-2018 10-K
29 11-01-2018 09-30-2018 10-Q
30 08-02-2018 06-30-2018 10-Q
31 05-03-2018 03-31-2018 10-Q
32 03-19-2018 12-31-2017 10-K
33 11-02-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-11-2017 03-31-2017 10-Q
36 03-08-2017 12-31-2016 10-K
37 11-03-2016 09-30-2016 10-Q
38 08-04-2016 06-30-2016 10-Q
39 05-05-2016 03-31-2016 10-Q
40 03-09-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

earnings-scheduled-for-november-7-2025
Earnings Scheduled For November 7, 2025
11/07/2025 11:11:23

gyre-therapeutics-q3-eps-003-beats-002-estimate-sales-30600m-miss-32930m-estimate
Gyre Therapeutics Q3 EPS $0.03 Beats $(0.0...
11/07/2025 11:07:34

Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0...

gyre-therapeutics-has-completed-patient-enrollment-in-the-52-week-phase-3-trial-in-china-of-pirfenidone-capsules-for-pneumoconiosis
Gyre Therapeutics Has Completed Patient En...
10/15/2025 11:05:16

A total of 272 patients have been enrolled in this multicenter, randomized, double-blind, placebo-controlled trial being conduc...

gyre-therapeutics-to-present-phase-3-liver-fibrosis-trial-results-at-aasld-2025
Gyre Therapeutics to Present Phase 3 Liver...
10/14/2025 11:18:04

Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advanc...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
10/10/2025 17:06:47

elastic-applied-digital-eightco-holdings-and-other-big-stocks-moving-higher-on-friday
Elastic, Applied Digital, Eightco Holdings...
10/10/2025 14:42:18

this-aptiv-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday
This Aptiv Analyst Begins Coverage On A Bu...
10/10/2025 13:25:06

jefferies-initiates-coverage-on-gyre-therapeutics-with-buy-rating-announces-price-target-of-16
Jefferies Initiates Coverage On Gyre Thera...
10/10/2025 11:28:09

Jefferies analyst Roger Song initiates coverage on Gyre Therapeutics (NASDAQ:GYRE) with a Buy rating and announces Price Tar...

gyre-therapeutics-gains-attention-as-under-the-radar-liver-fibrosis-drug-maker
Gyre Therapeutics Gains Attention As Under...
08/26/2025 18:53:44

HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billion potential and strong fib...

this-actuate-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-tuesday
This Actuate Therapeutics Analyst Begins C...
08/26/2025 11:49:01

hc-wainwright--co-initiates-coverage-on-gyre-therapeutics-with-buy-rating-announces-price-target-of-18
HC Wainwright & Co. Initiates Coverage On ...
08/26/2025 11:27:11

HC Wainwright & Co. analyst Matthew Keller initiates coverage on Gyre Therapeutics (NASDAQ:GYRE) with a Buy rating and a...

gyre-therapeutics-q2-sales-26771m-miss-30800m-estimate
Gyre Therapeutics Q2 Sales $26.771M Miss $...
08/11/2025 20:19:09

gyre-therapeutics-announces-first-dosing-in-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china
Gyre Therapeutics Announces First Dosing I...
06/10/2025 11:08:15

mac-copper-ats-pony-ai-and-other-big-stocks-moving-higher-on-tuesday
MAC Copper, ATS, Pony AI And Other Big Sto...
05/27/2025 14:56:40

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
05/23/2025 17:06:46

ross-stores-deckers-outdoor-xerox-holdings-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Ross Stores, Deckers Outdoor, Xerox Holdin...
05/23/2025 12:38:38

reported-earlier-gyre-therapeutics-prices-20m-offering-of-222m-common-shares-at-9share-to-fund-f351-trial-for-mash-related-liver-fibrosis
Reported Earlier, Gyre Therapeutics Prices...
05/23/2025 06:43:59

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
05/22/2025 21:05:56

gyre-therapeutics-announces-proposed-underwritten-public-offering-size-not-disclosed
Gyre Therapeutics Announces Proposed Under...
05/22/2025 20:12:28

gyre-therapeutics-hydronidone-meets-primary-endpoint-in-pivotal-phase-3-trial-evaluating-efficacy-and-safety-for-treatment-of-liver-fibrosis-in-patients-with-chronic-hepatitis-b-in-china
Gyre Therapeutics' Hydronidone Meets Prima...
05/22/2025 20:03:07

Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs. 29.84%, P=0.0002).Demonstrat...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION